Q2 EPS Forecast for Keros Therapeutics Reduced by Analyst

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Analysts at Leerink Partnrs lowered their Q2 2025 earnings per share (EPS) estimates for shares of Keros Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings of ($1.16) per share for the quarter, down from their prior forecast of ($1.02). The consensus estimate for Keros Therapeutics' current full-year earnings is ($4.74) per share. Leerink Partnrs also issued estimates for Keros Therapeutics' Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.73) EPS, FY2026 earnings at ($5.21) EPS, FY2027 earnings at ($4.69) EPS, FY2028 earnings at ($2.54) EPS and FY2029 earnings at ($3.24) EPS.

A number of other brokerages have also weighed in on KROS. Piper Sandler decreased their price objective on shares of Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a report on Friday, January 17th. Guggenheim restated a "neutral" rating on shares of Keros Therapeutics in a report on Friday, January 17th. Wells Fargo & Company decreased their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, February 27th. Wedbush restated a "neutral" rating and issued a $15.00 price objective on shares of Keros Therapeutics in a report on Tuesday, April 1st. Finally, Scotiabank decreased their target price on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research note on Monday. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $37.00.

Keros Therapeutics Price Performance

NASDAQ KROS traded up $0.09 during mid-day trading on Friday, reaching $13.74. The stock had a trading volume of 1,223,003 shares, compared to its average volume of 825,130. Keros Therapeutics has a 1 year low of $9.12 and a 1 year high of $72.37. The stock has a market cap of $558.05 million, a PE ratio of -2.64 and a beta of 1.32. The company has a fifty day moving average price of $12.20 and a 200 day moving average price of $24.23.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, topping analysts' consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $211.25 million for the quarter, compared to analysts' expectations of $84.62 million. During the same period in the previous year, the firm posted ($1.21) EPS.

Insider Transactions at Keros Therapeutics

In related news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of Keros Therapeutics stock in a transaction dated Wednesday, April 9th. The stock was purchased at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the purchase, the insider now directly owns 4,392,737 shares of the company's stock, valued at approximately $44,498,425.81. This trade represents a 27.01% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 20.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Entropy Technologies LP bought a new position in Keros Therapeutics in the 1st quarter worth $121,000. Invesco Ltd. boosted its holdings in Keros Therapeutics by 163.7% in the 1st quarter. Invesco Ltd. now owns 33,266 shares of the company's stock worth $339,000 after buying an additional 20,650 shares during the period. Covestor Ltd boosted its holdings in Keros Therapeutics by 1,230.8% in the 1st quarter. Covestor Ltd now owns 17,061 shares of the company's stock worth $174,000 after buying an additional 15,779 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Keros Therapeutics by 339.5% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 128,103 shares of the company's stock valued at $1,305,000 after purchasing an additional 98,957 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Keros Therapeutics by 31.1% during the 1st quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company's stock valued at $26,151,000 after purchasing an additional 609,212 shares during the last quarter. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.